Related Experiment Videos
Expression of pS2 protein in transitional cell bladder tumours
1Department of Pathology, University of Kuopio, Finland.
The Journal of Pathology
|August 1, 1994
Summary
pS2 protein is expressed in 40% of bladder tumors. While higher expression correlated with poorer survival, pS2 protein lacks independent clinical significance beyond established prognostic factors for bladder cancer.
Area of Science:
- Oncology
- Pathology
Background:
- pS2 protein is a marker of interest in various cancers.
- Its role in bladder transitional cell carcinoma prognosis requires further elucidation.
Purpose of the Study:
- To investigate the expression of pS2 protein in bladder cancer specimens.
- To determine the correlation between pS2 expression and clinicopathological features and patient survival.
Main Methods:
- Immunohistochemical analysis of pS2 protein expression in 201 bladder cancer biopsies.
- Statistical analysis to correlate pS2 expression with tumor differentiation, invasiveness, metastasis, patient age, and other molecular markers.
Main Results:
- pS2 protein was expressed in 40% of transitional cell bladder tumors.
- Higher pS2 expression was observed in poorly differentiated, invasive tumors with lymph node metastasis.
- Tumors with >10% pS2-positive cells showed a trend towards lower survival probability.
- pS2 expression was independent of DNA ploidy, S-phase fraction, mitotic index, and expression of c-erbB-2, p53, and EGFR.
Conclusions:
- pS2 protein is expressed in a significant subset of bladder cancers.
- Despite some correlations with adverse features, pS2 expression does not appear to offer independent prognostic value over established factors in bladder cancer.